Return to search results
Avapritinib
Ayvakit (avapritinib) is a prescription oral tablet medication manufactured by Blueprint Medicines Corporation. It acts as a kinase inhibitor, specifically targeting tyrosine kinases, and is used to treat certain cancers like gastrointestinal stromal tumors and systemic mastocytosis. Available in strengths of 25mg, 50mg, 100mg, 200mg, and 300mg. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Ayvakit (avapritinib) is a prescription oral tablet medication manufactured by Blueprint Medicines Corporation. It acts as a kinase inhibitor, specifically targeting tyrosine kinases, and is used to treat certain cancers like gastrointestinal stromal tumors and systemic mastocytosis. Available in strengths of 25mg, 50mg, 100mg, 200mg, and 300mg. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Avapritinib",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Avapritinib — ANDA 212608 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212608"
}
]
|
| identifier | ANDA212608 |
| issued | 2016-09-16 |
| keyword |
[
"drug-information",
"drug-manufacturers",
"fda",
"medications",
"pharmaceuticals"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Avapritinib |
